Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.04 Analyst target: $5.50 Upside: 169.61%
Sera Prognostics Inc. is a pioneering force in maternal-fetal health, focusing on cutting-edge diagnostic solutions designed to enhance pregnancy outcomes. Its flagship product, the PreTRM test, harnesses a unique biomarker platform to accurately evaluate the risk of preterm birth, enabling healthcare providers to implement timely and impactful interventions. With a steadfast commitment to advancing prenatal diagnostics and addressing pivotal health challenges, Sera is strategically positioned for significant growth within the maternal health sector, offering investors compelling opportunities for long-term value creation.
See the full interactive analysis & chart →Informational only — not investment advice.